In glioblastoma (GBM), pharmacological inhibition of FTO (e.g., using FB23-2) increases m6A modification on the target gene VEGFA, downregulating its expression and impairing DNA damage repair (e.g., sustaining γH2AX foci and reducing Rad51 recruitment). This evidence concerns the gene VEGFA and glioblastoma.